CONTRIBUCION DE LA PET CON 11C-METIONINA EN PACIENTES TRATADOS DE GLIOMAS CON RM NO CONCLUYENTE PARA LA DIFERENCIACION ENTRE RECURRENCIA TUMORAL Y RADIONECROSIS
Palabras clave:
poster, seram, glioma, 11C-MetioninaResumen
Objetivos
Valorar la contribución de la 11C-Metionina-PET en el manejo de los pacientes tratados de gliomas en la diferenciación precoz entre recurrencia tumoral vs radionecrosis.
Material y métodos
Treinta pacientes diagnosticados de glioma de alto grado tratados con cirugía+radioterapia+quimioterapia (5-18 meses) con hallazgos RM indeterminados a los que se efectuó 11C-Metionina PET (<15 días).
Análisis visual de 11C-Metionina-PET: grado de intensidad y morfología de captación. Cálculo de relación SUVmáximo delesión y SUVmedio del lóbulo contralateral (L/F). Fusión PET/RM por software (SPM8) tras efectuar secuencia T1-3D en la misma sesión.
El manejo de los pacientes se decidió en el comité de neuro-oncología: seguimiento clínico-imagen, tratamiento de segunda línea o cirugía.
Descargas
Citas
Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-MethioninePET: Visual Assessment versus Quantitative Assessment. Minamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, Matsunaga S, Shuto T, Akabane A, Miyata Y, Sakai S, Kubota K. PLoS One. 2015. 13; 10: e0132515.
Diagnosed recurrent glioma and antiangiogenic treatment response by 11C-Methionine PET. García JR, Baquero M, Bassa P, Soler M, Moragas M, Riera E. Rev Esp Med Nucl Imagen Mol. 2015; 34: 398-9.
Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. Miwa K, Matsuo M, Ogawa S, Shinoda J, Yokoyama K, Yamada J, Yano H, Iwama T. Radiat Oncol. 2014 14; 9: 181.
C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas. D'Souza MM, Sharma R, Jaimini A, Panwar P, Saw S, Kaur P, Mondal A, Mishra A, Tripathi RP. Clin Nucl Med. 2014; 39: 791-8.
C-Methionine positron emission tomographic imaging of biologic activity of a recurrent glioblastoma treated with stereotaxy-guided laser-induced interstitial thermotherapy. Galldiks N, von Tempelhoff W, Kahraman D, Kracht LW, Vollmar S, Fink GR, Schroeter M, Goldbrunner R, Schmidt M, Maarouf M. Mol Imaging. 2012; 11: 265-71.
Diagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue Necrosis. Shishido H, Kawai N, Miyake K, Yamamoto Y, Nishiyama Y, Tamiya T. Cancers (Basel). 2012 1; 4: 244-56..
Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW, Jung HW, Chang KH. Clin Neurol Neurosurg. 2010; 112: 758-65.
Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, Deckert M, Heiss WD, Jacobs AH. J Nucl Med. 2009; 50: 1962-8.
Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. Dandois V, Rommel D, Renard L, Jamart J, Cosnard G. J Neuroradiol. 2010; 37: 89-97.
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J, Ten Haken RK, Lawrence TS, Cao Y, Tsien C. Int J Radiat Oncol Biol Phys. 2009. 1;73: 479-85.
Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, Maruyama T, Muragaki Y, Iwama T. AJNR Am J Neuroradiol. 2008; 29: 1867-71.
Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K. J Nucl Med. 2008; 49: 694-9.
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, Herholz K. Eur J Nucl Med Mol Imaging. 2006; 33: 516-24.
Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma.
Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Nishikawa M, Ohata K, Torii K, Morino M, Nishio A, Hara M. Ann Nucl Med. 2004; 18: 291-6.
Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L. Eur J Nucl Med Mol Imaging. 2005; 32: 39-51.
Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T. Neurol Med Chir (Tokyo). 1998; 38: 342-7; discussion 347-8.
Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Ogawa T, Kanno I, Shishido F, Inugami A, Higano S, Fujita H, Murakami M, Uemura K, Yasui N, Mineura K, et al. Acta Radiol. 1991; 32: 197-202.
Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions.
Lilja A, Lundqvist H, Olsson Y, Spännare B, Gullberg P, Långström B. Acta Radiol. 1989; 30: 121-8.
